Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2012 |
| End Date: | July 2012 |
| Contact: | Noli C Raz, Jr., RN |
| Email: | nraz.researchrn@yahoo.com |
| Phone: | 714-263-7323 |
A Phase 1, Open-label, Randomized, Crossover Study to Assess the Safety, Tolerability, and Efficacy of CLP With and Without Spironolactone in Adults With Heart Failure
The purpose of this study is to determine the effects of CLP, with and without
spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic
kidney disease.
We found this trial at
1
site
Click here to add this to my saved trials
